These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24989696)

  • 1. Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.
    Adusumilli PS
    Cancer; 2014 Nov; 120(21):3268-71. PubMed ID: 24989696
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciduoid pleural mesothelioma in an adolescent.
    Arango-Tomás E; Algar-Algar FJ; Salvatierra Velázquez A
    Arch Bronconeumol; 2013 May; 49(5):218-9. PubMed ID: 23265622
    [No Abstract]   [Full Text] [Related]  

  • 4. [Malignant pleural mesothelioma: further options].
    van Hezik EJ
    Arch Bronconeumol; 2005 Dec; 41(12):703. PubMed ID: 16373048
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
    Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
    Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel combinations using pemetrexed in malignant mesothelioma.
    Gadgeel SM; Pass HI
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S61-6. PubMed ID: 15117427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
    Kao SC; McCaughan B; Muljono A; Boyer M
    J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new front line treatment for malignant pleural mesothelioma?
    Steele JP
    Thorax; 2003 Feb; 58(2):96-7. PubMed ID: 12554885
    [No Abstract]   [Full Text] [Related]  

  • 11. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
    Rusch VW
    J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
    [No Abstract]   [Full Text] [Related]  

  • 12. Pemetrexed combination improves mesothelioma survival.
    Kerr C
    Lancet Oncol; 2005 Aug; 6(8):548. PubMed ID: 16094758
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
    Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant mesothelioma.
    Muñoz A; Barceló R; López-Vivanco G
    N Engl J Med; 2006 Jan; 354(3):305-7; author reply 305-7. PubMed ID: 16422026
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
    Nowak AK; Cook AM; McDonnell AM; Millward MJ; Creaney J; Francis RJ; Hasani A; Segal A; Musk AW; Turlach BA; McCoy MJ; Robinson BW; Lake RA
    Ann Oncol; 2015 Dec; 26(12):2483-90. PubMed ID: 26386124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
    Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
    Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
    Suwanrusme H; Meyer ML; Green MR
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S56-60. PubMed ID: 15117426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.